A recent study (9) has shown a dramatical improvement in survival with immunotherapy (programmed death-ligand 1 [PD-(L)1] cytotoxic T-lymphocyte-associated antigen 4 [CTLA-4] blockage) in metastatic or non-metastatic MSI/dMMR CRC and reported new treatment recommendations for this unique CRC population. This evidence concerns the gene CD274 and colorectal carcinoma.